How many clinical trials are tracked for Parkinson's Disease?

450 trials are tracked, 22 with published results.

Parkinson's Disease Research

Parkinson's Disease: current evidence & treatments

Parkinson's disease (PD) involves complex genetic, molecular, and clinical factors. Genetic studies have identified strong risk factors: heterozygous GBA1 L444P carriers have 9.19-fold higher odds of PD ⁹, and bipolar disorder is associated with a 3.65-fold higher risk ³. A meta-analysis of young-onset PD identified six novel loci ⁴. Mitochondrial dysfunction and RNA editing alterations are implicated, with mitochondrial polygenic scores linked to alpha-synuclein seeding in LRRK2-related PD ¹⁷ and heterogeneous RNA editing changes observed in patients ¹⁸. The exercise-microbiota-queuine-tRNA axis may influence mitochondrial function and proteostasis ¹.

Diagnostic and therapeutic advances include QSM MRI showing distinct iron deposition patterns differentiating PD from atypical parkinsonian syndromes ⁷. Continuous subcutaneous foslevodopa/foscarbidopa improves off time in PD patients regardless of prior DBS ⁸. Deep brain stimulation (DBS) improves motor function and reduces levodopa needs irrespective of GBA mutation status ¹⁶, and modestly improves freezing of gait ²². Non-pharmacological interventions show mixed results: sensory cueing improves gait velocity and stride length ¹⁵, but combined motor-cognitive therapy shows no clear advantage over motor rehabilitation alone ¹², and VR is equally effective as physiotherapy for balance ¹⁴. Music therapy may improve cognition and neuropsychiatric symptoms ¹¹, and acupuncture moderately improves sleep quality ²³.

Pharmacological trials have had limited success. Prasinezumab showed non-significant delay in motor progression ¹⁰, and GLP-1 agonists showed no significant motor benefit but improved quality of life slightly ²¹. However, Nuplazid (pimavanserin) is FDA-approved for PD psychosis based on a trial showing significant reduction in hallucinations and delusions [24,25]. Current non-motor symptom classifications fail to capture the complexity of PD ². The HMC3 microglial model illuminates neurodegenerative mechanisms ⁵, and AI applications are being explored for protein misfolding diseases ¹⁹. Nocebo effects can be induced through negative verbal suggestion ²⁰, and nutrient interventions show inconsistent clinical translation ⁶.

GBA1 L444P carriers have 9.19-fold higher odds of PD ⁹; bipolar disorder increases risk 3.65-fold ³.

QSM MRI reveals distinct iron deposition patterns differentiating PD from atypical parkinsonian syndromes ⁷.

Continuous subcutaneous foslevodopa/foscarbidopa improves off time in PD ⁸.

DBS improves motor function and reduces levodopa needs regardless of GBA mutation status ¹⁶.

Nuplazid (pimavanserin) is FDA-approved for PD psychosis [24,25].

AI-generated synthesis of 25 cited studies, updated Jun 12, 2026. How we use AI.

‹ Prev 1 2 3 4 … 8 Next ›

Questions about Parkinson's Disease

How does the P-BANN framework help analyze proteomics data for Parkinson disease research?

The P-BANN framework uses a biologically annotated neural network with Bayesian variable selection to identify key proteins and pathways from proteomics data, aiding Parkinson disease research.

Full answer →

How does my perception of my illness affect my quality of life with Parkinson disease?

Your perception of Parkinson's — how you view its impact and control — can significantly affect your quality of life, sometimes more than the severity of motor symptoms alone.

Full answer →

Can a soft robotic exoskeleton help improve my walking speed and stride length?

Yes, a soft robotic exoskeleton can improve walking speed and stride length in people with Parkinson disease, based on recent studies showing significant gains after 4 weeks of training.

Full answer →

Is there a link between ferroptosis and Parkinson's disease immune responses?

Yes, ferroptosis and immune responses are linked in Parkinson's disease through a bidirectional cycle where neuroinflammation promotes iron-dependent cell death, which in turn amplifies immune activation.

Full answer →

Do patients with Parkinson's disease and mild cognitive impairment have different brain volumes?

Yes, patients with Parkinson's disease and mild cognitive impairment have smaller brain volumes in several subcortical regions, including the hippocampus, thalamus, putamen, and amygdala, compared to those with normal cognition.

Full answer →

Does deep brain stimulation help reduce freezing of gait in Parkinson's disease?

Yes, deep brain stimulation can reduce freezing of gait in Parkinson's disease, especially when used without medication, but individual responses vary.

Full answer →

Can acupuncture help improve sleep quality for people with Parkinson's disease?

Yes, acupuncture can improve sleep quality in Parkinson's disease, with systematic reviews and trials showing significant benefits on sleep scales, though more high-quality research is needed.

Full answer →

See all 7 questions about Parkinson's Disease →

Parkinson's Disease

Subtypes of Parkinson's Disease

Clinical Trials for Parkinson's Disease

Parkinson's Disease: current evidence & treatments

Key drugs in the evidence

Latest findings

Questions about Parkinson's Disease